Table 1.
Univariate analysis of XRCC1 and OGG1 polymorphisms with the risk of cholangiocarcinoma in Khon Kaen, Thailand
| Cases |
Controls |
|||||||
|---|---|---|---|---|---|---|---|---|
| Genetic polymorphisms | n | Per cent | n | Per cent | OR* | 95% CI | p Value | |
| XRCC1 G399A† | ||||||||
| GG | 62 | 38.8 | 149 | 44.0 | 1.0 | |||
| GA | 94 | 58.8 | 169 | 49.9 | 1.3 | 0.89 to 1.97 | 0.17 | |
| AA | 4 | 2.5 | 21 | 6.2 | 0.5 | 0.16 to 1.42 | 0.18 | |
| GA or AA (any A allele) | 98 | 61.3 | 190 | 56.1 | 1.2 | 0.82 to 1.78 | 0.33 | |
| OGG1 C326G‡ | ||||||||
| CC | 34 | 23.5 | 95 | 28.9 | 1.0 | |||
| CG | 109 | 75.2 | 229 | 69.6 | 1.4 | 0.86 to 2.23 | 0.18 | |
| GG | 2 | 1.4 | 5 | 1.5 | 1.2 | 0.22 to 7.03 | 0.80 | |
| CG or GG (any G allele) | 111 | 76.6 | 234 | 71.1 | 1.4 | 0.86 to 2.22 | 0.18 | |
| Joint effects | ||||||||
| XRCC1 G399A | OGG1 C326G | |||||||
| GG | CC | 14 | 9.7 | 41 | 12.7 | 1.0 | ||
| GA | CC | 19 | 13.1 | 47 | 14.5 | 0.3 | 0.15 to 0.55 | <0.001 |
| AA | CC | 2 | 1.4 | 4 | 1.2 | 3.5 | 1.10 to 14.60 | 0.03 |
| GG | CG | 42 | 29.0 | 100 | 30.9 | 0.1 | 0.07 to 0.25 | <0.001 |
| GA | CG | 56 | 38.6 | 108 | 33.3 | 0.1 | 0.07 to 0.22 | <0.001 |
| AA | CG | 3 | 2.1 | 15 | 4.6 | 0.9 | 0.42 to 2.07 | 1.00 |
| GG | GG | 5 | 3.4 | 3 | 0.9 | 4.7 | 1.30 to 25.33 | 0.01 |
| GA | GG | 2 | 1.4 | 4 | 1.2 | 3.5 | 1.10 to 14.60 | 0.03 |
| AA | GG | 2 | 1.4 | 2 | 0.6 | 7.0 | 1.61 to 63.46 | 0.004 |
| p Value for interaction=0.21 | ||||||||
*Crude OR from matched case–control analysis.
†DNA samples for XRCC1 genotyping were successfully carried out for 160 out of 175 cases, and 339 out of 350 controls.
‡DNA samples for OGG1 genotyping were successfully carried out for 145 out of 175 cases, and 329 out of 350 controls.